Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus

Open access

Abstract

Objective: This study aimed to evaluate the association between metformin treatment and the risk of neurodegenerative disease (ND) among elderly adults with type 2 diabetes mellitus (T2DM). Design/Setting/Participants: This retrospective longitudinal cohort study examined the effects of the length of metformin exposure on ND among elderly US veterans with T2DM and insulin treatment using the Veterans Affairs electronic medical record database. Primary and secondary outcome measures: The primary clinical outcome was defined as diagnosis of ND including dementia, Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and mild cognitive impairment during the follow-up period. The secondary clinical outcomes were separately measured by AD, PD, HD, dementia and mild cognitive impairment. Result: Adjusted by propensity score weight, a total of 5528 patients (mean age, 63.2±10.9 years; male, 98%; white, 60%) with a median follow-up of 5.2 years were selected. Those with ND or other mental disorders at baseline or who were on insulin for less than two-thirds of the study period were excluded. The incidence rate of ND was 11.48 per 1000 person-years among patients with metformin treatment, compared with 25.45 per 1000 person-years for those without metformin. Compared with no metformin use, 2–4 years and >4 years of metformin exposure were significantly associated with lower risk of ND (adjusted HR (aHR)=0.62, 95% CI 0.45 to 0.85; aHR=0.19, 95% CI 0.12 to 0.31, respectively), while metformin exposure in the first 2 years showed no significant influence. Conclusion: We conclude that long-term metformin therapy (>2 years) was associated with lower incidence of ND among elderly veterans with T2DM. We need to conduct a study with more representative population and more robust method for causal inferences. Further investigation into the mechanism involved is needed along with randomised trials to confirm a potential neuroprotective effect of metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2018-024954

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Incidence rates of clinical outcomes by metformin exposure status. Black bar: number of cases per 1000 person-years among patients who never received metformin treatment for indicated disease. Grey bar: number of cases per 1000 person-years among patients who received any length of metformin treatment for indicated disease. ND, neurodegenerative disease.
Figure 1 Incidence rates of clinical outcomes by metformin exposure status. Black bar: number of cases per 1000 person-years among patients who never received metformin treatment for indicated disease. Grey bar: number of cases per 1000 person-years among patients who received any length of metformin treatment for indicated disease. ND, neurodegenerative disease.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 49 references

Cited by

See all 147

Metadata

Authors
Shi, Q., Liu, S., Fonseca, V. A., Thethi, T. K., & Shi, L.
Affiliations
Tulane University (US)
Corresponding author
Shi, Lizheng
Venue
BMJ Open
Publisher
BMJ
Published
2019-07
Volume
9
Issue
7
Pages
e024954
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2964394554
Cited by
144
References
49
Citations by year
2026: 11 · 2025: 21 · 2024: 18 · 2023: 33 · 2022: 28 · 2021: 15 · 2020: 17 · 2019: 1
FWCI
12.12
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
National Institute of General Medical Sciences (U54GM104940)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
metformin, neurodegenerative diseases, type 2 diabetes, veterans, Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia, mild cognitive impairment, insulin therapy, neuroprotection, drug exposure duration
MeSH terms
Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Metformin, Middle Aged, Retrospective Studies, Risk Factors, United States, Veterans, Comorbidity, Incidence, Proportional Hazards Models, Neurodegenerative Diseases, Propensity Score

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1136/bmjopen-2018-024954
The paper
Shi, Q., Liu, S., Fonseca, V. A., Thethi, T. K., & Shi, L. (2019). Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. BMJ Open. https://doi.org/10.1136/bmjopen-2018-024954

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.